Simon Mallal

Simon Mallal

Auto-generated profile, based on publicly available information

Simon Mallal

Department of Medicine, Vanderbilt University Medical Center, 1161 21st Avenue South, Nashville, TN, 37232, USA; Institute for Immunology and Infectious Diseases, Murdoch University, Building 390, Discovery Way, Murdoch, WA, 6150, Australia

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 October 2020 in Science
Verified
Journal Article
Open access
PDF file
JMJose Mateus
Jose Mateus
AGAlba Grifoni
Alba Grifoni
Alison TarkeAlison Tarke
Alison Tarke
JSJohn Sidney
John Sidney
SRSydney I. Ramirez
Sydney I. Ramirez
DWDaniela Weiskopf
Daniela Weiskopf
Preexisting immune response to SARS-CoV-2: Robust T cell responses to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus occur in most individuals with coronavirus disease 2019 (COVID-19). Several studies have reported that some people who have not been exposed to SARS-CoV-2 have preexisting reactivity to SARS-CoV-2 sequences. The immunological mechanisms underlying this preexisting reactivity are not clear, but previous exposure to widely circulating common cold coronaviruses might be involved. Mateus et al. found that the preexisting reactivity against SARS-CoV-2 comes from memory T cells and that cross-reactive T cells can specifically recognize a SARS-CoV-2 epitope as well as the homologous epitope from a common cold coronavirus. These findings underline the importance of determining the impacts of preexisting immune memory in COVID-19 disease severity. Science , this issue p. 89

1 January 2018 in The Journal of Allergy and Clinical Immunology: In Practice
Verified
Journal Article
Closed access
KWKatie D. White
Katie D. White
RARiichiro Abe
Riichiro Abe
MAMichael Ardern-Jones
Michael Ardern-Jones
TBThomas Beachkofsky
Thomas Beachkofsky
CBCharles Bouchard
Charles Bouchard
EPElizabeth J. Phillips
Elizabeth J. Phillips

1 July 2019 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
KKKatherine C. Konvinse
Katherine C. Konvinse
JTJason A. Trubiano
Jason A. Trubiano
RPRebecca Pavlos
Rebecca Pavlos
IJIan James
Ian James
CSChristian M. Shaffer
Christian M. Shaffer
EPElizabeth J. Phillips
Elizabeth J. Phillips

13 August 2021 in Pathogens and Immunity
Verified
Journal Article
Open access
PDF file
SLShay Leary
Shay Leary
SGSilvana Gaudieri
Silvana Gaudieri
MPMatthew Parker
Matthew Parker
ACAbha Chopra
Abha Chopra
IJIan James
Ian James
SMSimon Mallal
Simon Mallal
Background: Genetic variations across the SARS-CoV-2 genome may influence transmissibility of the virus and the host’s anti-viral immune response, in turn affecting the frequency of variants over time. In this study, we examined the adjacent amino acid polymorphisms in the nucleocapsid (R203K/G204R) of SARS-CoV-2 that arose on the background of the spike D614G change and describe how strains harboring these changes became dominant circulating strains globally. Methods: Deep-sequencing data of SARS-CoV-2 from public databases and from clinical samples were analyzed to identify and map genetic variants and sub-genomic RNA transcripts across the genome. Results: Sequence analysis suggests that the 3 adjacent nucleotide changes that result in the K203/R204 variant have arisen by homologous recombination from the core sequence of the leader transcription-regulating sequence (TRS) rather than by stepwise mutation. The resulting sequence changes generate a novel sub-genomic RNA transcript for the C-terminal dimerization domain of nucleocapsid. Deep-sequencing data from 981 clinical samples confirmed the presence of the novel TRS-CS-dimerization domain RNA in individuals with the K203/R204 variant. Quantification of sub-genomic RNA indicates that viruses with the K203/R204 variant may also have increased expression of sub-genomic RNA from other open reading frames. Conclusions: The finding that homologous recombination from the TRS may have occurred since the introduction of SARS-CoV-2 in humans, resulting in both coding changes and novel sub-genomic RNA transcripts, suggests this as a mechanism for diversification and adaptation within its new host.

13 January 2017 in Retrovirology
Verified
Journal Article
Open access
PDF file
JSJori Symons
Jori Symons
ACAbha Chopra
Abha Chopra
EMEva Malatinkova
Eva Malatinkova
WSWard De Spiegelaere
Ward De Spiegelaere
SLShay Leary
Shay Leary
PCPaul U. Cameron
Paul U. Cameron
Assessing the location and frequency of HIV integration sites in latently infected cells can potentially inform our understanding of how HIV persists during combination antiretroviral therapy. We developed a novel high throughput sequencing method to evaluate HIV integration sites in latently infected cell lines to determine whether there was virus replication or clonal expansion in these cell lines observed as multiple integration events at the same position. We modified a previously reported method using random DNA shearing and PCR to allow for high throughput robotic processing to identify the site and frequency of HIV integration in latently infected cell lines. Latently infected cell lines infected with intact virus demonstrated multiple distinct HIV integration sites (28 different sites in U1, 110 in ACH-2 and 117 in J1.1 per 150,000 cells). In contrast, cell lines infected with replication-incompetent viruses (J-Lat cells) demonstrated single integration sites. Following in vitro passaging of the ACH-2 cell line, we observed a significant increase in the frequency of unique HIV integration sites and there were multiple mutations and large deletions in the proviral DNA. When the ACH-2 cell line was cultured with the integrase inhibitor raltegravir, there was a significant decrease in the number of unique HIV integration sites and a transient increase in the frequency of 2-LTR circles consistent with virus replication in these cells. Cell lines latently infected with intact HIV demonstrated multiple unique HIV integration sites indicating that these cell lines are not clonal and in the ACH-2 cell line there was evidence of low level virus replication. These findings have implications for the use of latently infected cell lines as models of HIV latency and for the use of these cells as standards.

1 July 2020 in Cell Reports
Verified
Journal Article
Open access
CSCinque Soto
Cinque Soto
RBRobin G. Bombardi
Robin G. Bombardi
MKMorgan Kozhevnikov
Morgan Kozhevnikov
RSRobert S. Sinkovits
Robert S. Sinkovits
ECElaine C. Chen
Elaine C. Chen
JCJames E. Crowe
James E. Crowe
The collection of T cell receptors (TCRs) generated by somatic recombination is large but unknown. We generate large TCR repertoire datasets as a resource to facilitate detailed studies of the role of TCR clonotypes and repertoires in health and disease. We estimate the size of individual human recombined and expressed TCRs by sequence analysis and determine the extent of sharing between individual repertoires. Our experiments reveal that each blood sample contains between 5 million and 21 million TCR clonotypes. Three individuals share 8% of TCRβ- or 11% of TCRα-chain clonotypes. Sorting by T cell phenotypes in four individuals shows that 5% of naive CD4+ and 3.5% of naive CD8+ subsets share their TCRβ clonotypes, whereas memory CD4+ and CD8+ subsets share 2.3% and 0.4% of their clonotypes, respectively. We identify the sequences of these shared TCR clonotypes that are of interest for studies of human T cell biology.